- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:58 | Ascentage raises $126m in first biotech IPO of 2025 | 1 | pharmaphorum | ||
| 01:00 | ASCENTAGE-B (06855): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| Fr | Ascentage Has First U.S. Biotech IPO of 2025, Raising $126M to Bring Its Cancer Meds to the World | 3 | MedCity News | ||
| Fr | Ascentage Pharma IPO opens flat at $17.25 | 1 | Investing.com | ||
| Fr | Ascentage Pharma IPO startet ohne Kursveränderung | 1 | Investing.com Deutsch | ||
| ASCENTAGE PHARMA GROUP INTERNATIONAL ADR Aktie jetzt für 0€ handeln | |||||
| Fr | Ascentage Pharma IPO opens flat | 5 | Investing.com | ||
| Fr | Hong Kong-listed biotech Ascentage Pharma prices US IPO at $17.25 | 2 | Renaissance Capital | ||
| Fr | Obesity biotech Aardvark eyes IPO as Ascentage makes $126M Nasdaq debut | 5 | FierceBiotech | ||
| Fr | ASCENTAGE PHARMA GROUP INTERNATIONAL - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| Fr | BRIEF: Ascentage Pharma prices U.S. IPO at 20% discount, to raise up to $130 million | 3 | Bamboo Works | ||
| Fr | Ascentage Pharma shares slide ahead of ADS debut on Nasdaq | 1 | Investing.com | ||
| Fr | Ascentage prices first biotech IPO of 2025, raising $126M | 2 | BioPharma Dive | ||
| Fr | ASCENTAGE-B (06855): OFFERING OF AMERICAN DEPOSITARY SHARES AND ISSUANCE OF NEW ORDINARY SHARES UNDER THE GENERAL MANDATE | 1 | HKEx | ||
| Fr | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Announces Pricing of U.S. Initial Public Offering | 105 | GlobeNewswire (Europe) | ROCKVILLE, Md. and SUZHOU, China, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (Nasdaq: AAPG) (HKEX: 6855) announced today the pricing of its U.S. initial public offering of 7,325,000 American... ► Artikel lesen | |
| Mi | BMS, Takeda's Chinese partners file for IPOs, sending Ascentage, Biokin and Bao bundling toward listings | 28 | FierceBiotech | ||
| Mi | Takeda-backed Ascentage Pharma sets terms for $170M IPO | 14 | Seeking Alpha | ||
| Di | ASCENTAGE PHARMA GROUP INTERNATIONAL - 8-A12B, Registration of securities | - | SEC Filings | ||
| Di | Hong Kong-listed biotech Ascentage Pharma sets terms for $149 million US IPO | 3 | Renaissance Capital | ||
| Di | ASCENTAGE-B (06855): INSIDE INFORMATION AND OVERSEAS REGULATORY ANNOUNCEMENT - FURTHER UPDATES ON PROPOSED INITIAL PUBLIC OFFERING | - | HKEx | ||
| Di | ASCENTAGE PHARMA GROUP INTERNATIONAL - F-1/A, Registration statement for certain foreign private issuers | - | SEC Filings |
Seite:
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 51,38 | 0,00 % | Der neue KI-Star: Cathie Wood und Nancy Pelosi haben schon zugegriffen - Tempus AI wird zum Muss! | © Foto: Gorodenkoff / Stock.adobe.comAufgepasst Siri und Alexa! Olivia, die KI-gestützte Gesundheits-Concierge-App von Tempus AI, ist auf dem Weg. Allein ihre Ankündigung bescherte Tempus AI den besten... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,325 | 0,00 % | Recursion Pharmaceuticals (RXRX): Industrializing Drug Discovery with AI Amid J.P. Morgan's 'Neutral' Outlook | ||
| IMMUNOVANT | 23,050 | 0,00 % | Immunovant-CTO Jay Stout verkauft Aktien im Wert von 51.780 US-Dollar | ||
| HARMONY BIOSCIENCES | 38,010 | 0,00 % | Insider Selling: Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) CFO Sells 25,000 Shares of Stock | ||
| NEUPHORIA THERAPEUTICS | 4,490 | 0,00 % | Why Neuphoria Therapeutics Inc. (NEUP) Surged on Friday | ||
| QIAGEN | 44,020 | +0,63 % | Biotech Report: Qiagen behauptet, Evotec leichter | (shareribs.com) Frankfurt 20.01.2025 - Die Biotechnologie-Aktien tendierten im deutschen Handel überwiegend schwächer. Die Marktteilnehmer halten sich zurück, da Trump in den USA seine nächste Amtszeit... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 77,11 | 0,00 % | Expert Outlook: Praxis Precision Medicine Through The Eyes Of 5 Analysts | ||
| SUMMIT THERAPEUTICS | 23,750 | 0,00 % | Why Summit Therapeutics (SMMT) Is Skyrocketing Now | ||
| EVAXION BIOTECH | 6,050 | 0,00 % | Evaxion Biotech: Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01 | Trial remains on track for completion and data readout in the second half of 2025
COPENHAGEN, Denmark, January 15, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 36,140 | 0,00 % | Rappta Therapeutics enters into a global license agreement with SpringWorks Therapeutics for a pre-clinical first-in-class molecular glue targeting PP2A | Goal to accelerate development and commercialization of the lead asset RPT04402 for the treatment of a subset of uterine cancersFinancials include a $13 million upfront payment and potential... ► Artikel lesen | |
| 89BIO | 7,130 | 0,00 % | HC Wainwright Reiterates Buy Rating for 89bio (NASDAQ:ETNB) | ||
| ARVINAS | 18,140 | 0,00 % | ARVINAS, INC. - 8-K, Current Report | ||
| DOGWOOD THERAPEUTICS | 11,270 | 0,00 % | Pre-market Movers: Allurion Technologies, Nvni Group, Dogwood Therapeutics, Jupiter Neurosciences, Ctrl Group | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.15 A.M. ET).In the Green Allurion Technologies Inc. (ALUR) is up over 297%... ► Artikel lesen | |
| EVOTEC | 8,255 | +1,10 % | Evotec mit EILMELDUNG: Analysten rechnen mit unfassbarem Kursfeuerwerk - Das sind die Hintergründe! | ||
| STRUCTURE THERAPEUTICS | 28,220 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer | SAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen |
Das Unternehmen ASCENTAGE PHARMA GROUP INTERNATIONAL ADR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 17,300 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ASCENTAGE PHARMA GROUP INTERNATIONAL ADR finden Sie auf Wallstreet Online.
